We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

35 hedge funds and large institutions have $18.7M invested in Ovid Therapeutics in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.6% less ownership

Funds ownership: 31.77% → 26.16% (-5.6%)

14% less capital invested

Capital invested by funds: $21.7M → $18.7M (-$3.01M)

27% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 15

30% less funds holding

Funds holding: 50 → 35 (-15)

81% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 16

Holders
35
Holders Change
-15
Holders Change %
-30%
% of All Funds
0.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
11
Reduced
15
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$792K
2
Millennium Management
Millennium Management
New York
+$621K
3
BI
BVF Inc
California
+$518K
4
Wells Fargo
Wells Fargo
California
+$230K
5
Renaissance Technologies
Renaissance Technologies
New York
+$194K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$3.15M
2
BlackRock
BlackRock
New York
-$939K
3
Deutsche Bank
Deutsche Bank
Germany
-$453K
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$398K
5
State Street
State Street
Massachusetts
-$333K

OVID Hedge Fund Activity: Q2 2019 in Review

35 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2019, worth a combined $18.7M — down 14% from $21.7M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of OVID and 3 opened new positions — a net loss of 13 holders — while 15 trimmed existing stakes and 11 added.

The largest buyer was Vanguard Group, adding an estimated $792K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.15M sold.

  • 35 institutional investors held Ovid Therapeutics (OVID) as of Q2 2019, down from 50 in Q1 2019.
  • Funds reported $18.7M of Ovid Therapeutics stock for Q2 2019, down 14% quarter-over-quarter.
  • 3 funds opened new Ovid Therapeutics positions in Q2 2019 and 16 closed out, a net change of -13 holders.
  • The largest Ovid Therapeutics buyer in Q2 2019 was Vanguard Group, an estimated $792K added.
  • The largest Ovid Therapeutics seller in Q2 2019 was Armistice Capital, an estimated $3.15M sold.

Based on aggregated 13F filings for Q2 2019.